Lenalidomid Ratiopharm

Lenalidomide, the active ingredient in Lenalidomid Ratiopharm, is an immunomodulatory imide drug (IMiD) presented as an oral dosage form for oral use. It is indicated for the treatment of certain blood cancers such as multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomid Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies and related disorders. - Multiple myeloma: improves progression‑free and overall survival when combined with dexamethasone or other agents in adult patients. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and cytopenias in eligible adults. - Mantle cell lymphoma: used in relapsed or refractory disease to achieve disease control as part of combination therapy.

Lenalidomide may cause a range of adverse reactions, some of which are frequent and others that are less common but potentially serious.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require hydration. - Rash: mild skin eruptions that can be itchy. - Neutropenia: reduced neutrophil count increasing infection risk.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary malignancies: emergence of new cancers such as acute myeloid leukemia.

Before initiating therapy, clinicians should assess patient suitability and monitor for known risks. - Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception. - Thrombosis prophylaxis: consider anticoagulation in patients with additional risk factors. - Hematologic monitoring: regular CBC to detect neutropenia or anemia. - Renal function: adjust use in patients with impaired renal clearance. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Lenalidomide may interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce plasma concentrations. - Anticoagulants (e.g., warfarin): increased risk of bleeding.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity. - P-glycoprotein inhibitors (e.g., verapamil): could raise lenalidomide exposure. - Vaccines: live attenuated vaccines should be avoided during treatment.